GNMSF News and Press, Genmab A/S Dkk From 05/24/18

Genmab A/S ( OTCPK:GNMSF )( OTCPK:GMXAY )  announces that a Phase 3 clinical trial evaluating Arzerra (ofatumumab) plus bendamustine in patients with indolent B-cell non-Hodgkin lymphoma (iNHL) who have not responded to Roche's Rituxan (rituximab) failed to demonstrate a statistically ...

The following slide deck was published by Genmab A/S ADR in conjunction with this Read more ...

The following slide deck was published by Genmab A/S in conjunction with their 2018 Q1 earnings Read more ...

Genmab A/S (GNMSF) Q1 2018 Earnings Conference Call May 8, 2018 12:00 PM ET Executives Jan van de Winkel – President and Chief Executive Officer David Eatwell – Chief Financial Operator Analysts Michael Novod – Nordea James Quigley – JPMorgan W...

Genmab ( OTCPK:GNMSF ): Q1 EPS of DKK3.20 Revenue of DKK681M (+171.6% Y/Y) Press Release More news on: Genmab A/S, Genmab A/S ADR, Earnings news and commentary, Tech stocks news,

The following slide deck was published by Genmab A/S in conjunction with this Read more ...

Company Recap Cambridge, MA-based Unum Therapeutics ( UNUM ) was founded in 2014. The company has developed an antibody-coupled T-cell receptor [ACTR] platform that causes an individual’s cytotoxic T-lymphocytes [CTLs] to kill tumor cells when combined with tumor-specific antibodies...

Genmab A/S (GNMSF) Q4 2017 Results Earnings Conference Call February 21, 2018 12:00 a.m. ET Executives Jan van de Winkel - President and Chief Executive Officer David Eatwell - Chief Financial Officer Analysts Thomas Bowers - Danske Bank Sachin Jain - Bank of America Mich...

The following slide deck was published by Genmab A/S in conjunction with their 2017 Q4 earnings Read more ...

Genmab ( OTCPK:GNMSF ): FY Operating income of DKK1.34B. More news on: Genmab A/S, Genmab A/S ADR, Earnings news and commentary, Tech stocks news, Read more ...